A Phase III b, Single-arm, Multicenter, Optimal Dose Finding Study to Assess the Efficacy and Safety of P1101 in Japanese Patients With Polycythemia Vera (PV).
Latest Information Update: 11 Nov 2024
At a glance
- Drugs Ropeginterferon alfa-2b (Primary) ; Aspirin
- Indications Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Sponsors PharmaEssentia Corporation
Most Recent Events
- 08 Nov 2024 Status changed from recruiting to completed.
- 12 Sep 2023 Status changed from not yet recruiting to recruiting.
- 23 Aug 2023 New trial record